Effect Of Simvastatin On Endothelial Dysfunction, Fibrinolysis, Coagulation And Inflammation After Aneurysmal Subarachnoid Hemorrhage "SIMSAB"


Phase N/A Results

Trial Description

To investigate whether statins can restore endothelial cell damage, activate fibrinolysis, and improve coagulation and inflammation after aneurysmal subarachnoid hemorrhage.


  • Simvastatin Drug
    Intervention Desc: HMG-CoA reductase inhibitor; lowers cholesterol

Trial Design

Single center, prospective, randomized, double-blind, placebo-controlled trial.

Patient Involvement

Patients are randomized for simvastatin 80 mg a day or placebo for 14 days. Blood withdrawal and transcranial Doppler examination is performed before the study drug is started and at days 4, 7, 10, 14 and 17 after SAH.


Type Measure Time Frame Safety Issue
Primary The effect of simvastatin on parameters of endothelial function, fibrinolysis, coagulation and inflammation after SAH.
Secondary The occurrence of cerebral ischemia after SAH; outcome on the Glasgow Outcome Scale and AMC Linear Disability Scale at 3 and 6 months after SAH; the relation between vasospasm as observed on transcranial Doppler examination and parameters of fibrinolysis, coagulation, endothelium dysfunction and inflammation.


Academic Medical Centre